VolitionRx’s (VNRX) “Hold” Rating Reiterated at Benchmark

Benchmark reissued their hold rating on shares of VolitionRx (NYSE:VNRX) in a research report report published on Friday morning,Benzinga reports.

Separately, StockNews.com began coverage on shares of VolitionRx in a report on Wednesday, November 20th. They set a “sell” rating for the company.

VolitionRx Price Performance

Shares of NYSE:VNRX opened at $0.79 on Friday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The firm has a market capitalization of $73.57 million, a PE ratio of -2.21 and a beta of 1.10. The business’s 50 day moving average price is $0.69 and its 200-day moving average price is $0.68.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.